Pulmonary Embolism - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pulmonary Embolism - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H1 2015’, provides an overview of the Pulmonary Embolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Embolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pulmonary Embolism Overview 6
Therapeutics Development 7
Pipeline Products for Pulmonary Embolism - Overview 7
Pipeline Products for Pulmonary Embolism - Comparative Analysis 8
Pulmonary Embolism - Therapeutics under Development by Companies 9
Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes 10
Pulmonary Embolism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Pulmonary Embolism - Products under Development by Companies 14
Pulmonary Embolism - Products under Investigation by Universities/Institutes 15
Pulmonary Embolism - Companies Involved in Therapeutics Development 16
Bayer AG 16
Bristol-Myers Squibb Company 17
Daiichi Sankyo Company, Limited 18
F. Hoffmann-La Roche Ltd. 19
Pulmonary Embolism - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 27
apixaban - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
edoxaban tosylate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
rivaroxaban - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SMTP-7 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TRX-1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Pulmonary Embolism - Recent Pipeline Updates 39
Pulmonary Embolism - Dormant Projects 60
Pulmonary Embolism - Discontinued Products 61
Pulmonary Embolism - Product Development Milestones 62
Featured News & Press Releases 62
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 62
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 63
Oct 28, 2014: U.S. FDA Cardiovascular and Renal Drugs Advisory Committee Makes Recommendation on Daiichi Sankyo’s Once-Daily SAVAYSA for the Reduction in Risk of Stroke and Systemic Embolic Events in Patients with Non-Valvular Atrial Fibrillation 64
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 65
Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 66
Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 66
Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 68
May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 69
Feb 17, 2014: Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long-Term VTE Prevention 69
Dec 19, 2013: FDA Accepts For Review ELIQUIS Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis And Pulmonary Embolism, And For The Reduction In The Risk Of Recurrent DVT And PE 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables

Number of Products under Development for Pulmonary Embolism, H1 2015 7
Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Pulmonary Embolism - Pipeline by Bayer AG, H1 2015 16
Pulmonary Embolism - Pipeline by Bristol-Myers Squibb Company, H1 2015 17
Pulmonary Embolism - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 18
Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 26
Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H1 2015 39
Pulmonary Embolism - Dormant Projects, H1 2015 60
Pulmonary Embolism - Discontinued Products, H1 2015 61